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0014-5793  2012 Federation of European BiochemicPhosphoinositides regulate numerous cellular events via the recruitment and activation of multiple
lipid-binding effector proteins. The precise temporal and spatial regulation of phosphoinositide sig-
nals by the co-ordinated activities of phosphoinositide kinases and phosphatases is essential for
homeostasis and development. Mutations in two inositol polyphosphate 5-phosphatases, INPP5E
and OCRL, cause the cerebrorenal syndromes of Joubert and Lowe’s, respectively. INPP5E and OCRL
exhibit overlapping phosphoinositide substrate speciﬁcity and subcellular localisation, including an
association with the primary cilia. Here, we review recent studies that identify a new role for these
enzymes in the regulation of primary cilia function. Joubert syndrome has been extensively linked
to primary cilia defects, and Lowe’s may represent a new class of ‘ciliopathy associated’ syndromes.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Phosphoinositides are lipid signalling molecules which regulate
numerous cellular processes including vesicular trafﬁcking, cyto-
skeletal dynamics, protein synthesis, proliferation and survival.
The spatial and temporal localisation of phosphoinositide signals
is tightly regulated by phosphoinositide kinases and phosphatases
including the inositol polyphosphate 5-phosphatases (5-phospha-
tases) INPP5E and OCRL. Mutations in INPP5E and OCRL are associ-
ated with the human cerebrorenal syndromes of Joubert and
Lowe’s respectively [1,2]. Here we will discuss recent studies
reporting a role for these 5-phosphatases at the ‘antenna-like’ sig-
nalling centre, the primary cilia.
2. Primary cilia: structure, function and trafﬁcking to cilia
Primary cilia are sensory organelles that project from the sur-
face of most quiescent cells in vivo. The singular primary cilium
senses the extracellular environment and plays a critical role in
multiple signal transduction pathways. Primary cilia consist of a
basal body, transition zone, ciliary axoneme and ciliary membrane
(Fig. 1). The centrosome differentiates into the basal body during.A. Mitchell).
al Societies. Published by Elsevierciliogenesis and localises to the plasma membrane at the base of
the primary cilia. The basal body is continuous with the cilia axo-
neme, which consists of 9 microtubule doublets providing struc-
ture to the cilia and docking sites for transport proteins [3]. The
9 + 0 microtubule axoneme arrangement deﬁnes the primary cilia
as distinct from the 9 + 2 arrangement of the motile cilia. The cili-
ary membrane is continuous with the somatic plasma membrane,
however, the membrane domains are separated by a putative dif-
fusion barrier at the transition zone [4]. The protein, lipid and
phosphoinositide composition of the ciliary membrane is largely
undeﬁned. Ciliogenesis, the formation of cilia, is widely accepted
to occur when a cell exits the cell cycle, however, recent studies
challenge this contention, as pro-proliferative signalling pathways
depend on primary cilia for signal transduction [5,6].
Sorokin et al. (1962) [3] identiﬁed the key stages of primary cilia
assembly (Fig. 1). Initially, a Golgi-derived primary ciliary vesicle
attaches to the distal end of the mother centriole. The centriole ex-
tends distally via the acquisition of accessory structures, and dif-
ferentiates into a basal body. The resulting structure consists of
the ciliary bud (the site of microtubule assembly), or primitive axo-
neme, which is continuous with the mother centriole at one end
and is surrounded by the primary ciliary vesicle (now termed the
ciliary sheath) at the other. As the ciliary bud elongates by micro-
tubule assembly, the ciliary sheath extends by fusion with second-
ary ciliary vesicles. Finally, the ciliary vesicle fuses with the plasma
membrane and the axoneme continues to elongate by intraﬂagellar
transport (IFT) and microtubule assembly.B.V. Open access under CC BY-NC-ND license.
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Fig. 1. Phosphoinositide signalling and cilia. Phosphoinositides localise to the plasma membrane and the endomembrane domains where they specify organelle identity and
recruit speciﬁc lipid binding effector proteins. PtdIns(4)P is the major species present at the TGN, although low levels of PtdIns(4,5)P2 are also detected. PtdIns(4,5)P2 is the
predominant phosphoinositide at the plasma membrane where it serves as a substrate for PI3-kinase, which once activated by receptor tyrosine kinases, transiently generates
PtdIns(3,4,5)P3. Multiple PH domain containing proteins are recruited to PtdIns(3,4,5)P3 including Akt, Raf-GAPs and Arf-GAPs and regulate extensive downstream signalling
pathways. PI3-kinase signalling is regulated by lipid phosphatases such as the 3-phosphatase PTEN and the 5-phosphatases, including INPP5E and OCRL, which generate
PtdIns(3,4)P2. The phosphoinositide content of the ciliary membrane, which is separated from the somatic plasma membrane via a putative diffusion barrier at the transition
zone, remains to be explicitly deﬁned. Primary ciliogenesis is initiated when the primary ciliary vesicle fuses with the mother centriole. Additional Golgi derived vesicles fuse
with the primary ciliary vesicle, and the mother centriole differentiates into the basal body. The basal body then fuses with the plasma membrane and the axoneme elongates
by IFT and microtubule assembly.
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adult tissue homeostasis, in part via regulation of multiple cellular
signalling pathways. Components of the platelet-derived growth
factor (PDGF), hedgehog (Hh) and Wnt pathways, among others,
localise to the primary cilia and in some cases the cilia may be
essential for signal transduction [6–9]. Nodal cilia generate the
leftward ﬂuid ﬂow responsible for establishing left–right body
asymmetry. Furthermore, renal epithelial cilia sense ﬂuid ﬂow
and are required for renal homeostasis.
Trafﬁcking of membrane-associated and cytosolic proteins
within the primary cilia is facilitated by IFT which requires IFT B-
complex proteins and kinesin 2 to mediate anterograde transport,
a process essential for ciliogenesis. The IFT A-complex and dynein
in contrast facilitate retrograde IFT [10]. However, the molecular
mechanisms and processes that regulate trafﬁcking of proteins to
the primary cilia from the cytosol/endocytic network remain
poorly understood. Golgi-derived vesicles form the ciliary mem-
brane during ciliogenesis and multiple integral cilia membrane
proteins have been shown to trafﬁc via the trans-Golgi network(TGN), suggesting a role for the Golgi in cilia trafﬁcking, however,
the process is only beginning to be deﬁned [3].
3. Ciliopathy syndromes
Inherited mutations in essential cilia-associated genes result in
a spectrum of cilia dysfunction diseases collectively termed ciliop-
athy syndromes (Table 1). The major organs affected by ciliopathy
syndromes are the brain, kidney and eye. Although phenotypic var-
iability exists between affected individuals, common characteristic
features include cerebellar malformations, renal dysfunction (poly-
cystic kidneys or Nephronophthisis (NPHP): in the latter cysts are
observed in the corticomedullary border and tubular atrophy,
basement membrane defects and diffuse interstitial ﬁbrosis are
evident), cognitive impairment, retinal degeneration, polydactyly,
hypotonia and hyperpnoea/apnoea (reviewed in [11]). Signiﬁcant
allelism occurs within the ciliopathies whereby differing muta-
tions in a single gene can result in multiple syndromes depending
on the effect of the mutation on the protein product. For example
Table 1
Ciliopathy syndromes and associated genes.
Ciliopathy syndrome Abbreviation Genes
Joubert syndrome JSRD INPP5E, ARL13B, KIF7, CEP290, NPHP1, RPGRIP1L, TMEM67, TMEM216, TMEM138,
TMEM237, CC2D2A, AHI1, OFD1, TCTN1, TCTN2, CEP41, C5ORF42
Meckel-Gruber syndrome MKS NPHP3, CC2D2A, TMEM67, TMEM216, CEP290, TCTN2, RPGRIP1L, B9D1, B9D2, MKS1
Cerebellar vermis hypo/aplasia, oligophrenia, congenital
ataxia, ocular coloboma, and hepatic ﬁbrosis
COACH CC2D2A, TMEM67, RPGRIP1L
Nephronophthisis NPHP NPHP1, NPHP4, NPHP3, INVS, WDR19, TMEM67, TTC21B, NEK8, GLIS2
Mental retardation, truncal obesity, retinal dystrophy, and
micropenis
MORM INPP5E
Bardet-Biedl syndrome BBS C2orf86, BBS5, ARL6, BBS7, BBS12, PTHB1, TRIM32, BBS1, BBS10, CEP290, CEP290, TTC8,
BBS4, BBS2, MKS1, MKKS
Orofacial digital syndrome OFD1
Senior-Løken syndrome SLSN NPHP1, NPHP4, IQCB1, CEP290, SDCCAG8
Arima syndrome
Cogan-type congenital oculomotor apraxia NPHP1
Leber congenital amaurosis LCA LCA9, RPE65, CRB1, RD3, KCNJ13, LRAT, TULP1, LCA5, IMPDH1, CEP290, RPGRIP1L, RDH12,
SPATA7, AIPL1, GUCY2D, CRX
Hydrolethalus syndrome HLS KIF7, HYLS1
Acrocallosal syndrome ACLS KIF7
Asphyxiating thoracic dystrophy ATD TTC21B, IFT80, DYNC2H, ATD1
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CEP290 (OMIM ID: 610142), RPGRIP1L (OMIM ID: 610937) and
CC2D2A (OMIM ID: 612013), are mutated in both Joubert syndrome
and the more the severe Meckel-Gruber syndrome [12–19]. The
two syndromes associated with mutations in INPP5E are described
in more detail below.
3.1. Joubert syndrome
Joubert syndrome and related disorders (JSRD) are a genetically
and phenotypically heterogeneous group of autosomal or X-linked
recessive conditions united by the pathognomonic midbrain-hind-
brain malformation deﬁned as the molar tooth sign (MTS) on mag-
netic resonance imaging (MRI) [20,21]. Affected individuals also
exhibit developmental delay, ataxia, hypotonia, irregular breathing
and eye movements [20]. Joubert syndrome is variably associated
with extra-neural manifestations including postaxial polydactyly,
liver ﬁbrosis, NPHP, cystic renal dysplasia, ocular colobomas and
retinal dystrophy [20]. Mutations in 17 genes with established
roles in cilia structure, function or trafﬁcking have been linked to
Joubert syndrome (Table 1) [2,12–16,22–32].
3.2. MORM syndrome
MORM is a rare autosomal recessive genetic disorder which has
been described in a consanguineous Northern Pakistani family
[33]. MORM-affected individuals exhibit static moderate mental
retardation, truncal obesity, congenital retinal dystrophy and mi-
cro penis. The similar phenotypic features of MORM with Bardet-
Biedl syndrome (BBS)-affected individuals indicate MORM is a cil-
iopathy syndrome. To date MORM has only been associated with
mutations in INPP5E [34].
4. Molecular mechanisms of ciliopathy syndromes
The molecular mechanisms underlying ciliopathy syndromes
remain poorly deﬁned, although, all syndromes are united by a de-
fect in the structure and/or function of the primary cilium. Ciliop-
athy-associated proteins often function co-operatively in
multiprotein complexes and are implicated in the regulation of ci-
lia assembly, Golgi dynamics, microtubule modiﬁcations and sta-
bility, function of the putative diffusion barrier and trafﬁcking to
the cilia. As many of these processes are intimately linked, for
example defects in microtubule dynamics can inﬂuence Golgi traf-ﬁcking and ciliogenesis, it is unclear what the precise causative de-
fect is or whether it is a combination of these events. Aberrant
trafﬁcking of cilia localised transmembrane receptors is emerging
as a favoured model particularly for the Joubert/Meckel-Gruber
syndrome spectrum disorders.
Proteins are proposed to trafﬁc to the primary cilia via three po-
tential pathways; direct trafﬁcking from the Golgi to the cilia, traf-
ﬁcking to the plasma membrane and recycling into the primary
cilia, or alternatively lateral transport from the plasma membrane
through the putative diffusion barrier into the cilia [35]. Recent
studies have lead to an explosion in the identiﬁcation of proteins
that mediate trafﬁcking to the primary cilia via these pathways,
however, these studies have been in the context of multiple differ-
ent ciliary cargo proteins. Therefore, it is difﬁcult to draw a com-
plete picture of how these proteins function co-ordinately to
mediate trafﬁcking to the cilia. Furthermore, the primary cilia plays
an active role in multiple signalling pathways including Wnt, PDGF
and Hh, in which receptors trafﬁc into/out of the ciliary axoneme
during signal transduction [7–9]. The molecular machinery medi-
ating receptor trafﬁcking to the cilia under these conditions re-
mains to be deﬁned but potentially a distinct subset of cilia-
associated proteins may regulate trafﬁcking in basal versus stimu-
lated states.
Most Joubert syndrome-associated proteins form one of two
functionally overlapping complexes, Tectronic and NPHP, at the ci-
lia transition zone (between the basal body and the axoneme)
(Fig. 1) [29,31,36]. These complexes regulate ciliogenesis and act
as a diffusion barrier to specify protein composition of the ciliary
membrane. Loss of a Tectronic or NPHP complex component abro-
gates cilia localisation of cilia-associated proteins such as ARL13B
and Smoothened (Smo) [31]. The mammalian Tectronic complex
consists of TCTN1, TCTN2, TCTN3, MKS1, TMEM216, TMEM67,
CEP290, CC2D2A, B9D1 and studies in Caenorhabditis elegans (C.
elegans) suggest TMEM237 is also a component [31,32]. Mutations
in components of this complex cause Joubert syndrome, COACH or
Meckle-Gruber syndrome or all three syndromes depending on the
severity of the defect in complex function [31]. In contrast, the
NPHP complex consists of NPHP1, NPHP4 and RPGRIP1L which
when mutated result in NPHP or Senior-Løken syndrome [29].
Mutations in proteins that regulate the function of both complexes
(NPHP1 and RPGRIP1L) result in Meckle-Gruber syndrome and the
rare cases of Joubert syndrome with NPHP [31].
Interestingly, the Joubert syndrome proteins INPP5E, ARL13B,
KIF7, C5ORF42, TMEM138, ODF1, AHI1 and CEP41 have not been
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affected individuals with mutations in these genes exhibit Joubert
syndrome, but not Meckle-Gruber syndrome, NPHP or Senior-
Løken syndrome [2,22–27,30]. The roles C5ORF42, OFD1, CEP41
and INPP5E (discussed below) play in cilia function are little char-
acterised. However, notably ARL13B, KIF7, TMEM138 and AHI1
have been linked to trafﬁcking to the primary cilia and may there-
fore represent a novel group of proteins distinct from the Tectronic
or NPHP complexes that are involved in trafﬁcking to the primary
cilia. ARL13B is a member of the ARF family of GTPases which con-
stitutively localises to the primary cilia membrane [37–39].
Arl13bhennin mutant mice exhibit a classical ciliopathy syndrome
phenotype and at the molecular level aberrant trafﬁcking of Hh
pathway components to the primary cilia is observed [37,39].
The phenotype of Kif7/ mice is also consistent with a ciliopathy
syndrome and KIF7 knockdown retinal epithelial cells exhibit frag-
mentation of the Golgi and aberrant trafﬁcking [24,40,41]. In vitro
studies support a role for TMEM138 and AHI1 in regulating traf-
ﬁcking to the primary cilia [27,42]. Therefore as a collective, all
of the Joubert syndrome proteins examined to date in this context
have been shown to regulate trafﬁcking to the cilia. Future studies
on those proteins not yet characterised in this context, may reveal
all Joubert syndrome proteins mediate trafﬁcking to the cilia and
defects in this process may underlie the syndrome. Signiﬁcantly,
many ciliopathy-associated proteins function in multiprotein com-
plexes and notably many Joubert syndrome proteins complex with
Rab8.
Rab8 is one of the most well characterised regulators of cilia
trafﬁcking, and modulation of its localisation and/or activity may
be a common function shared by Joubert syndrome-associated pro-
teins. Rab8 localises to the primary cilia and the base of the photo-
receptor outer segment in its active GTP-bound conformation
[43,44]. In retinal photoreceptors CC2D2A is proposed to recruit
Rab8 to the cilia and is essential for Rab8 regulation of cilia func-
tion. Cc2d2a null zebraﬁsh phenocopy dominant negative Rab8
overexpressing zebraﬁsh, both exhibiting a characteristic ciliopa-
thy phenotype including Kupffer’s vesicle defects and delayed ret-
rograde melanosome transport in response to adrenaline
stimulation [43–45]. Rab8 regulates the trafﬁcking of multiple cilia
membrane receptors at the level of vesicle docking and fusion with
the base of the primary cilia. Overexpression of constitutively ac-
tive Rab8 in hTERT immortalized retinal pigmented epithelial
(hTERT-RPE) cells increases the length of the cilia membrane and
axoneme, suggesting increased docking of cilia-targeted vesicles
with the ciliary membrane [44]. CEP290 binds Rab8 under ciliated
and non-ciliated conditions, and its regulation of ciliogenesis is
dependent on its interaction with Rab8 [46]. AHI1 also interacts
with Rab8, recruiting it to the basal body and increasing cilia sta-
bility, therefore loss of AHI1 is proposed to result in ciliogenesis
and trafﬁcking defects due to Rab8 mislocalisation and degradation
[42]. Furthermore, Rab8 binds to the 5-phosphatase OCRL, an inter-
action required for ciliogenesis and rhodopsin localisation to the
primary cilia (discussed below) [47]. It is interesting to speculate
that Joubert syndrome proteins may all bind to Rab8 and facilitate
trafﬁcking of essential components to the cilia that are required ci-
lia stability, axoneme extension or transmembrane receptors for
signal transduction.
Defects in the localisation of transmembrane receptors to the
primary cilia due to aberrant trafﬁcking (mutations in ARL13B,
KIF7, CC2D2A, CEP290, TMEM216, TMEM138 and AHI1) or function
of the diffusion barrier at the transition zone (mutations in the
NPHP and Tectronic complexes) may explain aspects of the Joubert
syndrome phenotype. The molar tooth sign may result from altered
Hh or Wnt signalling, due to defective Smo or Frizzled trafﬁcking
respectively. Retinal degeneration may be a consequence of rho-
dopsin mislocalisation [48,49].Interestingly, extra-ciliary trafﬁcking functions are being identi-
ﬁed for traditionally deﬁned cilia-associated proteins. For example,
IFT complex B subunits IFT20, IFT57 and IFT88 form a complex in
non-ciliated T lymphocytes which is required for T cell receptor
(TCR) trafﬁcking to the immune synapse [50]. These data suggest
ciliopathy syndromes could result from more global defects in
intracellular protein trafﬁcking and the localisation of transmem-
brane receptors to the primary cilia, rather than as a consequence
of speciﬁc defects in ciliogenesis or cilia structure.
5. Phosphoinositide metabolism
Phosphoinositides localise to the inner leaﬂet of the plasma
membrane and endomembrane domains and consist of two fatty
acids and a glycerol backbone linked to a soluble inositol ring.
The inositol head group may be modiﬁed at the D3, D4 and D5
positions by phosphoinositide kinases and phosphatases to gener-
ate seven distinct signalling molecules. Although, phosphoinosi-
tides constitute only a minor proportion of total cellular
phospholipids, they play key roles in regulation of cellular function
via the recruitment and activation of phosphoinositide-binding
proteins, leading to the formation of molecular scaffolds and acti-
vation of many signalling pathways on speciﬁc membrane com-
partments [51]. The localisation of phosphoinositides to
endomembrane domains, which is tightly controlled by lipid ki-
nases and phosphatases, deﬁnes organelle identity.
One of the most well studied phosphoinositide metabolic path-
ways is the generation and regulation of PtdIns(3,4,5)P3 (and sub-
sequently PtdIns(3,4)P2) which is transiently produced by class IA
phosphoinositide 3-kinase (PI3-kinase) phosphorylation of
PtdIns(4,5)P2 in response to growth factor activation of receptor
tyrosine kinases (Fig. 1) [52]. Proteins containing pleckstrin homol-
ogy (PH) domains bind PtdIns(3,4,5)P3 and in some cases
PtdIns(3,4)P2 signals at the plasma membrane leading to their acti-
vation and downstream signal transduction [53]. PtdIns(3,4,5)P3 is
then dephosphorylated by 5-phosphatases (discussed below) to
generate PtdIns(3,4)P2, or is degraded by PTEN forming
PtdIns(4,5)P2 [54,55]. More than 250 PH domain-containing pro-
teins have been identiﬁed with diverse roles in cellular function
including regulation of proliferation, cell survival, cell growth,
metabolism, vesicular trafﬁcking and the actin cytoskeleton
[56–58]. The serine/threonine kinase Akt binds both
PtdIns(3,4,5)P3 and PtdIns(3,4)P2, enabling its activation by other
PtdIns(3,4,5)P3-dependent kinases including phosphoinositide
dependent kinase 1 (PDK1) and mTORC2 [53,59,60]. Active Akt
phosphorylates numerous signalling proteins to modulate their
activity and thereby regulates extensive downstream pathways.
Other PtdIns(3,4,5)P3 effectors include Grp1, ADP-ribosylation
factor guanine nucleotide-exchange factors (ARF-GEFs), ADP-
ribosylation factor GTPase activating proteins (ARF-GAPs) and
Rac-GEFs [59,61].
PtdIns(4)P is the predominant phosphoinositide at the TGN.
Knockdown of the PtdIns 4-kinase that synthesises PtdIns(4)P,
PI4IIa, abrogates TGN to plasma membrane trafﬁcking [62]. Arf1
stimulates PtdIns 4-kinase and functions as a co-receptor with
PtdIns(4)P to recruit trafﬁcking adaptors [63,64]. This results in
the recruitment of four-phosphate-adaptor protein (FPAP) 1 and
2 the clathrin adaptor proteins AP-1, and GGAs, thereby facilitating
clathrin coat assembly at the TGN [62,64,65].
PtdIns(4,5)P2 is the major phosphoinositide at the plasmamem-
brane where it is a key regulator of actin cytoskeletal dynamics.
PtdIns(4,5)P2 activates multiple actin regulatory proteins including
WASP family members, coﬁlin and gelsolin which mediate actin
nucleation, severing and capping respectively and thereby
promotes actin polymerisation [66–68]. PtdIns(4,5)P2 is also
present at low level on the TGN, and indeed phosphatidylinositol
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phosphatases INPP5E and OCRL localise to this organelle [64,69–
73]. Multiple PtdIns(4,5)P2 binding proteins such as dynamin and
Golgi spectrin localise to the TGN, however, the role PtdIns(4,5)P2
plays in Golgi trafﬁcking remains poorly deﬁned [74,75].
6. Phosphoinositides at the primary cilia
The phosphoinositide content of the primary cilia and the role
these phospholipids play at the cilia remains largely unknown.
Lobasso et al., (2010) [76] have shown no signiﬁcant difference
in the total phosphoinositide content of porcine olfactory ciliary
membranes compared to epithelial membranes. However, this
study did not examine the individual phosphorylated phosphoino-
sitides species present in the ciliary membrane, therefore regional
differences may exist. Several studies have indirectly detected
phosphorylated phosphoinositides in the primary ciliary mem-
brane. PtdIns(4,5)P2 phosphodiesterase activity is present in chan-
nel catﬁsh olfactory cilia and is stimulated in response to odorant
receptor activation [77]. In C. elegans, 5-phosphatase cil-1 trunca-
tion mutants exhibit ectopic PtdIns(3)P biosensor (2xFYVE do-
main) localisation to the cilia in male-speciﬁc sensory neurons
[78]. The ciliary receptors PDK-2 and LOV-1 are mislocalised in
cil-1 mutants, suggesting PtdIns(3)P and/or PtdIns(3,5)P2 may play
a role in C. elegans cilia trafﬁcking. Recently, two mammalian 5-
phosphatases, INPP5E and OCRL, have been localised to the pri-
mary cilia and are the focus of this review [34,47,79].
The exocyst is a multiprotein complex which mediates vesicle
tethering at the plasma membrane during exocytosis. Components
of the complex (Sec6 and Sec8) localise to base of the forming pri-
mary cilia during ciliogenesis, while Sec10 knockdown in MDCK
cells reduces cilia number and length [80,81]. Exo70, another com-
ponent of the exocyst, binds to PtdIns(4,5)P2 and PtdIns(3,4,5)P3,
and its ability to bind phosphoinositides is essential for recruit-
ment of the exocyst to the plasma membrane and exocytosis
[82]. The Tubby family member Tulp3 plays an important role in
neuronal development and negatively regulates the Hh signalling
pathway [83]. Tulp3 localises to the primary cilia and interacts
with the IFT-A complex mediating localisation of a subset of G-pro-
tein coupled receptors (GPCR) including the somatostatin receptor
3 (SSTR3) and melanin-concentrating hormone receptor 1
(MCHR1) to the primary cilia [84]. Tulp3 contains a phosphoinosi-
tide binding domain that interacts with PtdIns(4,5)P2, PtdIns(3,4)P2
and PtdIns(3,4,5)P3 and is required for MCHR1 trafﬁcking to the
primary cilia. Therefore PtdIns(4,5)P2, PtdIns(3,4)P2 and/or
PtdIns(3,4,5)P3 may localise to the primary cilia membrane to reg-
ulate cilia trafﬁcking. The ciliopathy syndrome-associated multi-
protein complex, the BBSome, functions as a planer coat complex
that mediates lateral transport of transmembrane receptors to pri-
mary cilia [85]. The complex component, BBS5, contains two phos-
phoinositide binding PH-GRAM domains and interacts with
PtdIns(3)P and to a lesser extent PtdIns(3,4)P2 and PtdIns(3,5)P2
as shown by phosphoinositide binding studies [44]. Furthermore,
BBSome binding to liposomes and the formation of coated proﬁles
on liposomes is enhanced in the presence of PtdIns(3,4)P2, suggest-
ing this phosphoinositide may mediate the recruitment of the
BBSome and facilitate coat formation [85].
7. The inositol polyphosphate 5-phosphatases
The 5-phosphatases are a family of 10 mammalian and 4 yeast
members which remove the D5 position phosphate from the inosi-
tol headgroup of phosphoinositides and inositol phosphates and
regulate diverse processes including embryonic development, re-
nal, neuronal and optic function, glucose homeostasis, the immuneresponse and spermatogenesis. The conserved 300 amino acid,
Mg2+ dependent 5-phosphatase domain exhibits a similar fold
and catalytic mechanism to the apurinic/apyrimidinic endonucle-
ases, [86,87]. INPP5B, OCRL, SHIP1, SHIP2, PIPP, SKIP, synaptojanin
1 and synaptojanin 2 exhibit overlapping substrate speciﬁcity,
hydrolysing Ins(1,4,5)P3 and Ins(1,3,4,5)P4 and PtdIns(3,4,5)P3,
PtdIns(4,5)P2 and in some cases PtdIns(3,5)P2. INPP5A, in contrast,
hydrolyses only Ins(1,4,5)P3 and Ins(1,3,4,5)P4 [88,89].
The 5-phosphatase family members contain multiple protein–
protein interacting domains which provide speciﬁcity of function
to these enzymes. Synaptojanin 1/2 and SHIP1/2 contain proline-
rich domains (PRDs) mediating interactions with Src homology
(SH) 3 domains. SH2 domains in SHIP1/2 bind phosphotyrosine
residues in activated cell surface receptors. OCRL and INPP5B con-
tain a microtubule binding [Abnormal spindle-like microcephaly-
associated protein/spindle pole body/hydrin] (ASH) domain and
an inactive RhoGAP domain. These domains specify subcellular
localisation and mediate the formation of multiprotein complexes
to regulate 5-phosphatase activity.
Despite overlapping substrate speciﬁcity and broad tissue
expression patterns, the 5-phosphatases generally exhibit non-
redundant roles in cellular function. Inpp5e, Skip, Ship1/2 and Synj1
knockout mice exhibit signiﬁcant and distinct phenotypes ranging
from embryonic lethality to myeloproliferation and neurological
dysfunction [34,90–93]. Furthermore, affected individuals with IN-
PP5E or OCRL mutations exhibit the severe developmental disor-
ders, Joubert syndrome and Lowe’s syndrome respectively [1,2].
Speciﬁcity of function is also likely gained by distinct subcellular
localisation and protein–protein interactions.
8. INPP5E and ciliopathy syndromes Joubert and MORM
INPP5E [also known as the 72 kDa 5-phosphatase (mouse), ino-
sitol polyphosphate 5-phosphtase IV (human) and Pharbin (rat)] is
encoded by the INPP5E gene located on chromosome 9q34.3
[70,94,95]. INPP5E hydrolyses membrane-associated phosphoino-
sitides PtdIns(4,5)P2, and compared to SHIP1 and OCRL exhibits
the highest in vitro activity towards PtdIns(3,4,5)P3 [70,95]. Some
in vitro evidence suggests INPP5E may also hydrolyse PtdIns(3,5)P2
[70]. INPP5E is widely expressed, with enrichment in the brain and
testis [70]. In dividing cells INPP5E exhibits a cytosolic distribution
with perinuclear/TGN enrichment, potentially mediated by its N-
terminal PRD [70]. In ciliated cells, the C-terminal CAAX motif is
proposed to facilitate its localisation to the primary cilium [34]. IN-
PP5E is also expressed in macrophages where it localises to the
phagocytic cup during phagocytosis [96].
INPP5E negatively regulates PI3-kinase/Akt signalling in vitro
and in vivo. Overexpression of INPP5E sensitises cells to Fas-in-
duced apoptosis and reduces PI3-kinase mediated Akt phosphory-
lation following PDGF, or insulin like growth factor simulation
[97,98]. In vivo INPP5E PtdIns(3,4,5)P3 5-phosphatase activity is
stimulated by its recruitment to the PI3-kinase p85 subunit and
insulin receptor substrates in response to insulin stimulation. In-
pp5e siRNA knockdown in rats induces hypothalamic
PtdIns(3,4,5)P3 accumulation and consequently reduced food in-
take and body mass [99].
9. INPP5E mutations and ciliopathy syndromes
All reported Joubert syndrome INPP5E mutations cluster in the
5-phosphatase domain and disrupt the charge of evolutionally con-
served basic residues located on the surface of the protein (Fig. 2)
[2,100]. Mutants exhibit variably reduced catalytic activity to-
wards PtdIns(4,5)P2 and more dramatically towards PtdIns(3,4,5)P3
in vitro, but retain ciliary localisation [2]. Joubert syndrome muta-
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Fig. 2. INPP5E and OCRL domain structure and disease causing mutations. INPP5E Joubert syndrome mutations (blue) cluster in the 5-phosphatase domain [2,100]. INPP5E
MORM mutations (arrow) result in deletion of the 18 C-terminal amino acids [34]. Lowe’s syndrome missense, nonsense and in-frame deletion mutations in OCRL (pink) are
distributed throughout the length of the protein [105,149,150]. OCRL Dent 2 disease missense and nonsense mutations (purple) generally cluster at the N-terminal region of
the protein. Mutations (green) occur in both Lowe’s syndrome and Dent 2 disease. (Frameshift and splicing mutations are not shown).
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the surface of the 5-phosphatase domain. Therefore complex
mechanism(s) of protein misfunction, such as defects in protein–
protein interaction and/or subcellular localisation, as well as dis-
rupted phosphoinositide metabolism, may be responsible for Jou-
bert syndrome pathogenesis.
Mutations in INPP5E have also been identiﬁed in MORM syn-
drome [34]. The pathogenic INPP5E mutation in MORM syndrome
results in deletion of the 18 C-terminal amino acids including the
highly conserved CAAX motif (Fig. 2) [34]. This mutation restricts
INPP5E to proximal regions of the primary cilia and reduces its
association with 14-3-3, but does not impair in vitro 5-phospha-
tase catalytic activity.
10. Molecular mechanisms of INPP5E dysfunction in ciliopathy
syndromes
Inpp5e/ mice exhibit embryonic or early post natal lethality
and recapitulate key features of the ciliopathy syndromes, thereby
providing an ideal model to study the role INPP5E plays at the cilia
and in ciliopathies [34]. Inpp5e/ embryos exhibit exencephaly,
polydactyly, bilateral anopthalmos, polycystic kidneys and skeletalmalformations. Tamoxifen induced Inpp5e knockout in 4 week old
mice induces obesity, retinal degeneration and cystic kidneys, but
does not affect 6 month survival [34].
Inpp5e/mouse embryonic ﬁbroblasts (MEFs) assemble cilia in
response to serum starvation at a similar rate to wild type MEFs.
However, the proportion of ciliated Inpp5e/ MEFs is signiﬁcantly
reduced compared to wild type upon serum stimulation, a pheno-
type rescued by treatment of cells with the PI3-kinase inhibitor
LY294002. This suggests cilia stability is reduced in Inpp5e/
MEFs. Jacoby et al. (2009) [34] hypothesised that cilia stability is
controlled by ciliary localised growth factor receptors (such as
PDGFRa), which, once activated by serum, lead to ciliary
PtdIns(3,4,5)P3 production and cilia disassembly. Therefore, ele-
vated PtdIns(3,4,5)P3 signals in the Inpp5e/ cilia are proposed
to induce more rapid cilia disassembly, although neither the local-
isation or levels of PtdIns(3,4,5)P3 were examined. Altered cilia sta-
bility also has not been shown in vivo and how reduced stability
contributes to the phenotype of the Inpp5e/ mouse is unknown.
INPP5E may play a role in trafﬁcking under non-ciliated condi-
tions. INPP5E localises to the primary cilia and the Golgi [34,70]. In
adipocytes, INPP5E overexpression induces GLUT4 translocation
and insertion into the plasma membrane [101]. In macrophages
2852 S.E. Conduit et al. / FEBS Letters 586 (2012) 2846–2857INPP5E localises to the phagocytic cup following Fcc receptor acti-
vation and regulates pseudopod extension and phagosome closure
[96]. A growing body of evidence indicates deregulated trafﬁcking
to the primary cilia and/or mislocalisation of cilia-associated
receptors may be common molecular mechanisms associated with
ciliopathy syndromes.
The phenotype of Inpp5e/ mice is signiﬁcantly more severe
(embryonic lethality and exencephaly) than the phenotype exhib-
ited by Joubert-affected individuals with INPP5E mutations (cere-
bellar MTS) [2,34,102]. This is also the case for multiple other
Joubert syndrome-associated genes including ARL13B, KIF7,
CC2D2A, TCTN1 and TCTN2 [31,37,40]. The lethal phenotypes of
Cc2d2a and Tctn2 knockout mice more closely resemble Meckel-
Gruber syndrome in which CC2D2A and TCTN2 mutations have
been identiﬁed [17,31,103]. Furthermore, KIF7 mutations have re-
cently been associated with foetal lethal hydrolethalus and acroc-
allosal, which share common features with Kif7/ mice [40,104].
Nonsense and frameshift KIF7 mutations cause hydrolethalus and
acrocallosal, whereas Joubert syndrome-affected individuals exhi-
bit in-frame KIF7 deletions [24,40]. Therefore partial loss of func-
tion of ciliopathy-associated proteins may result in the relatively
mild Joubert syndrome phenotype, whereas total loss of function
may lead to severe developmental disorders and embryonic lethal-
ity. Interestingly, Joubert syndrome INPP5E mutations are located
on the surface of the 5-phosphatase domain and reduce 5-phos-
phatase catalytic activity but do not inﬂuence subcellular localisa-
tion [34]. The effect of these mutations on protein expression is
unknown, but reduced expression of Joubert syndrome INPP5E
mutants may explain the reduced enzyme activity associated with
all Joubert syndrome INPP5E mutants, irrespective of the position
of the mutation relative to the catalytic domain. This is analogous
to the location of Dent 2 disease mutations in OCRL (discussed be-
low) which are predicted to result in the expression of a partially
functional protein [105]. Lowe’s syndrome mutations, in contrast,
result in a complete loss of function of OCRL and a more severe
phenotype than Dent 2 disease. Therefore, it is possible INPP5E
mutations that prevent its expression or lead to a complete loss
of function of INPP5E may cause a severe embryonically lethal phe-
notype, consistent with Inpp5e/ mice.
11. OCRL, Lowe’s syndrome and Dent 2 disease
The OCRL protein (also called Lowe’s protein), which is mutated
in the oculocerebrorenal syndrome of Lowe (OCRL), is encoded by
the OCRL gene located on chromosome Xq25. OCRL exhibits a
broader substrate proﬁle than INPP5E and hydrolyses the 5-posi-
tion phosphate from the inositol ring of Ins(1,4,5)P3, Ins(1,3,4,5)P4,
PtdIns(3,4,5)P3, PtdIns(3,5)P2 and PtdIns(4,5)P2, however,
PtdIns(4,5)P2 is its preferred in vivo substrate [106,107]. OCRL is
widely expressed with enrichment in the brain and the kidneys
[71,108]. The 105 kDa OCRL protein contains the conserved 5-
phosphatase catalytic domain, an ASH domain, RhoGAP domain
and PH domain mediating interactions with trafﬁcking effectors
and adaptors [109,110]. OCRL localises to multiple compartments
in the endocytic network including the early endosomes, endocytic
clathrin-coated pits, the Golgi and to the basal body and in a
minority of cells to the ciliary axoneme [47,69,71,72,79,111–113].
12. Lowe’s syndrome
Lowe’s syndrome is a rare X-linked congenital disorder charac-
terised by renal Fanconi syndrome (including low-molecular-
weight proteinuria, hypercalciuria and aminoaciduria), congenital
cataracts, mental retardation, maladaptive behaviour, rickets,
hypotonia and areﬂexia [114,115]. Lowe’s syndrome is exclusivelycaused by mutations in OCRL [1]. Missense mutations commonly
occur in the 5-phosphatase, ASH, RhoGAP and Rab binding do-
mains, disrupting folding, PtdIns(4,5)P2 5-phosphatase catalytic
activity, protein–protein interactions and/or reducing protein sta-
bility (Figure ure2) [109,111,113,116–122]. Nonsense mutations
have been reported in the 3’ region of the OCRL gene and result
in expression of a truncated protein [1,123]. These mutations
may lead to an absence of the protein or a complete loss of function
[105]. Notably, regardless of the nature of the mutations, Lowe’s
ﬁbroblasts exhibit reduced PtdIns(4,5)P2 5-phosphatase activity
[113].
13. Dent 2 disease
Dent 2 disease is also caused by mutations in the OCRL gene.
Dent 2 disease is a rare X-linked disorder related to Lowe’s syn-
drome. However, patients exhibit a less severe and predominantly
renal restricted phenotype including renal Fanconi syndrome, mild
mental retardation and rickets [124]. Missense mutations also oc-
cur in the OCRL 5-phosphatase domain in Dent 2 disease, but are
distributed over the surface of the protein impairing 5-phospha-
tase activity and are unlikely to affect folding (Fig. 2) [105]. Inter-
estingly, this is reminiscent of the localisation of Joubert syndrome
mutations in INPP5E [34]. Nonsense and frameshift mutations have
been reported in the N-terminal region of OCRL including the PH
domain, which result in the expression of a catalytically functional
truncated protein [105,124]. In contrast to Lowe’s syndrome, Dent
2 disease is proposed to result from a partial loss of OCRL function.
14. Molecular mechanisms of Lowe’s syndrome and Dent 2
disease
Despite the dramatic phenotypes exhibited by affected individ-
uals with OCRL mutations, Ocrl/mice are viable, fertile and exhi-
bit no phenotype [108]. This may be due to functional redundancy
with another 5-phosphatase family member, namely Inpp5b, which
has a similar domain structure, substrate speciﬁcity and shares
common binding partners. Inpp5b/ mice are viable but exhibit
testicular degeneration post sexual maturity and infertility
[108,125]. Signiﬁcantly, Ocrl/;Inpp5b/ mice are embryonically
lethal and no live embryos are detected at embryonic day (E) 9.5,
suggesting functional redundancy during early development
[108]. Early embryonic lethality is inconsistent with the ciliopathy
mouse models, as mice with mutations in cilia-associated genes
generally exhibit midgestation lethality at approximately E10.5 –
E15.5 [126]. To generate an appropriate mouse model that accu-
rately recapitulates the key features of Lowe’s syndrome Bothwell
et al. (2011) [127] generated Ocrl/;Inpp5b/ mice that express
human INPP5B. These mice exhibit reduced growth, aminoaciduria
and proteinuria and may provide key insights into Lowe’s syn-
drome and Dent 2 disease pathogenesis in the future. Fibroblasts
from Lowe’s-affected individuals exhibit elevated PtdIns(4,5)P2
signals, the preferred substrate of OCRL, compared to healthy con-
trols [72,107,113]. The widely accepted view in the literature is
that OCRL regulates PtdIns(4,5)P2-dependent processes including
actin cytoskeletal dynamics, cytokinesis and in particular vesicular
trafﬁcking, and that deregulation of these events accounts for the
Lowe’s syndrome phenotype [128–130].
OCRL binds to Rab family members Rab1, Rab5, Rab6, Rab14,
Rab31, Rab35 and notably Rab8 [109,130,131]. Rab1, Rab6 and
Rab31 mediate OCRL localisation to the TGN and Lowe’s mutants
which do not bind Rabs, do not localise to the endocytic network
[132]. In vitro, Rab binding stimulates OCRL 5-phosphatase cata-
lytic activity. Therefore OCRL is proposed to function on endomem-
branes to restrict PtdIns(4,5)P2 and generate PtdIns(4)P signals and
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RhoGAP domains interact with clathrin and regulate multiple
clathrin-dependent trafﬁcking processes [110,112,133]. OCRL co-
localises with clathrin, transferrin (Tf) and the cation-independent
mannose-6-phosphate receptor (CI-MPR) on clathrin-coated vesi-
cles [112]. Aberrant OCRL expression blocks retrograde trafﬁcking,
resulting in CI-MPR and adaptor protein-1 (AP-1) mislocalisation
to endosomes [112,133]. Furthermore, OCRL regulates anterograde
trafﬁcking of the cation-dependent mannose-6-phosphate receptor
(CD-MPR) [131]. Interestingly, Lowe’s-affected individuals exhibit
elevated serum lysosomal enzymes which may be due to altered
MPR trafﬁcking and thereby secretion of lysosomal hydrolases by
default trafﬁcking pathways [134]. OCRL also modulates TfR endo-
cytosis at clathrin coated vesicles in association with clathrin and
the adaptor AP-2 [112,135].
Defects in megalin and TrkA trafﬁcking may explain the renal
and neurological features of Lowe’s syndrome respectively. Mega-
lin is a scavenger receptor that mediates reabsorption of proteins
and solutes from urine [136]. Megalin knockout mice and individ-
uals with Lowe’s syndrome both exhibit lowmolecular weight pro-
teinuria. The TrkA receptor plays an important role in neuronal
signalling [137]. OCRL interacts with the Rab5 effectors APPL1
and Ses1/2 on the early endosomes [111,122,138]. APPL1 binding
bridges OCRL to [GAIP-interacting protein, C terminus] (GIPC),
which is reported to regulate megalin and TrkA trafﬁcking [111].Table 2
Comparison of INPP5E and OCRL associated ciliopathy syndrome with ‘classical’ ciliopathy
Classical Ciliopathy Syndrome
Human disease Joubert syndrome
Meckel-Gruber syndrome
COACH
Nephronophthisis
Senior–Løken syndrome
MORM
Orofacial digital syndrome
Cerebellar-ocular-renal syndrome
Dekaban-Arima syndrome
Cogan-type congenital oculomotor apraxia
Leber congenital amaurosis
Hydrolethalus
Acrocallosal
Major tissues affected Brain
Eye
Kidney
Pathology Cerebellar vermis hypoplasia (MTS)
Retinal degeneration
Nephronophthisis/polycystic kidneys
Mouse models Embryonic lethality
Exencephaly/anencephaly/holoprosencephaly
Cerebellar hypoplasia
Neural tube patterning defects
Polydactyly
Anophthalmia/microphthalmia/retinal degene
Skeletal abnormalities
Craniofacial defects
Polycystic kidneys
Laterality defects
Male infertility
Obesity
Zebraﬁsh models Curved tail
Cystic pronephroi
Pigmentation defects
Laterality defects
Hydrocephalus
Abnormal ear otolith formation
Microphthalmia
Proposed molecular mechanism(s) Cilia structure/function
Trafﬁcking to cilia
Cilia transition zone complex
Cilia signallingReduced megalin shedding is detected in Lowe’s urine, suggesting
decreased kidney tubule plasma membrane megalin levels, which
may result from defective megalin trafﬁcking [139,140]. Addition-
ally, ectopic early endosomal PtdIns(4,5)P2 accumulates in Lowe’s-
affected renal cells and OCRL knockdown cells, leading to aberrant
F-actin polymerisation and a block in megalin trafﬁcking at early
endosomes [141].
OCRL localises to the epithelial cell junctions in MDCK cells at
the early stages of polarisation [142]. OCRL knockdownMDCK cells
exhibit reduced height and mislocalisation of apical markers
including ezrin, gp135 and F-actin. These cells fail to form cysts
when grown in 3D culture, further supporting a polarity defect.
Therefore OCRL is proposed to be essential for maturation of the
polarising epithelium [142,143].
Although Lowe’s syndrome does not ﬁt the classical ciliopathy
syndrome phenotype proﬁle, Lowe’s syndrome affects the same or-
gans as ciliopathy syndromes, including brain, kidney and eye, and
three recent studies have shown OCRL regulates ciliogenesis and
trafﬁcking to the cilia (Table 2) [47,79,143]. Lowe’s syndrome-af-
fected ﬁbroblasts and OCRL knockdown NIH3T3 and hTERT-RPE
cells exhibit reduced cilia number and cilia length in vitro
[47,79]. However, cilia length is increased in OCRL knockdown
MDCK cells, suggesting tissue speciﬁc defects in cilia function
[143]. OCRL predominantly localises to the basal body and in a
small proportion of cells at the cilia axoneme, however, Lowe’ssyndromes.
INPP5E OCRL
Joubert syndrome
MORM
Lowe’s Syndrome
Dent 2 Disease
Brain
Eye
Kidney
Brain
Eye
Kidney
Cerebellar vermis hypoplasia (MTS) Mental retardation
Congenital cataracts
Renal Fanconi syndrome
ration
Embryonic/early post natal lethality
Exencephaly/anencephaly
Polydactyly
Anophthalmos
Skeletal abnormalities
Polycystic kidneys
Cleft palate
No phenotype
Not reported Curved tail
Cystic pronephroi
Pigmentation defects
Laterality defects
Oedema
Hydrocephalus
Microphthalmia
Cilia stability Trafﬁcking (Megalin, TrkA)
Cytoskeleton
Cytokinesis
2854 S.E. Conduit et al. / FEBS Letters 586 (2012) 2846–2857mutant proteins fail to exhibit this distribution and localise to per-
inuclear puncta. Signiﬁcantly, ocrl morpholino knockdown zebra-
ﬁsh exhibit mislocalised melanophores, laterality defects, curved
tail and dilated cystic pronephroi with disorganised/longer cilia,
characteristic of a ciliopathy phenotype [47,79,143]. Coon et al.
(2012) [47] reported reduced Kupffer vesicle cilia number/length
in ocrl knockdown zebraﬁsh, whereas Rbaibi et al. (2012) [143]
suggests Kupffer vesicle cilia are normal, therefore further studies
will be required to fully deﬁne the extent of cilia dysfunction with
loss of OCRL.
OCRL is proposed to be essential for ciliogenesis via regulation
of trafﬁcking. OCRL knockdown abrogates rhodopsin localisation
to the primary cilia and OCRL forms a complex with Rab8 and
Ses1/2, which is required for cilia assembly [47]. Rab8 mediates
trafﬁcking from the Golgi to the primary cilia, and Ses1/2 localises
to the early endosomes and is required for endocytosis. Therefore
OCRL is proposed to act in two independent trafﬁcking pathways
to the cilia; direct TGN to cilia trafﬁcking in complex with Rab8
and cilia trafﬁcking of endocytosed proteins with Ses1/2.
In the kidney OCRL plays an established role in megalin trafﬁck-
ing. Interestingly, megalin family members bind cilia signalling
pathway ligands, Shh and Wnt, mediating endocytosis and down-
stream signalling [144–146]. Although the relevance of this obser-
vation remains to be shown, megalin mediated Shh endocytosis by
astrocytes is essential for oligodendrocyte progenitor development
and Lowe’s syndrome-affected individuals show evidence of demy-
elination [131,147,148]. Therefore deregulated trafﬁcking and cili-
ary signalling may potentially play a role in aspects of Lowe’s
pathogenesis. Trafﬁcking, polarity and cilia structure/function are
tightly linked processes and defects in one process may lead to
abnormalities in the others, making it difﬁcult to delineate the pri-
mary underlying defect. Many lines of evidence support a role for
OCRL in trafﬁcking irrespective of cell type, as trafﬁcking precedes
and is required for cell polarisation, speciﬁcation and maintenance
of cilia, dysregulated trafﬁcking is a likely underlying molecular
mechanism for the observed defects. Other typical cilia-associated
proteins including IFT20, IFT57 and IFT88 have been implicated in
extra-ciliary trafﬁcking, suggesting global defects in trafﬁcking
may play a role in ciliopathy pathogenesis [50]. However, whether
cilia dysfunction is pathogenic in Lowe’s syndrome remains to
be determined. Therefore, Lowe’s syndrome may potentially
represent a novel ciliopathy or ‘ciliopathy associated’ syndrome
(Table 2).
The phosphoinositide-binding proteins Tulp3 and the BBSome
localise to the primary cilia and the Tulp3 PtdIns(4,5)P2,
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 binding site is essential for
MCHR1 trafﬁcking to the primary cilia [84,85]. The BBSome binds
PtdIns(3,4)P2 and the formation of coated proﬁles on liposomes
is enhanced by PtdIns(3,4)P2 [85]. Therefore, ciliary phosphoinosi-
tides may regulate the spatial and temporal activity of speciﬁc
effector proteins. Under basal conditions phosphoinositides may
act as docking sites to anchor proteins such as Tulp3 or the BBSome
to the cilia membrane and upon stimulation, a different phosphor-
ylated phosphoinositide species may recruit/activate a speciﬁc
subset of lipid binding proteins. In this model mutations in INPP5E
and OCRL which decrease 5-phosphatase activity (via reduced
expression, enzyme activity or mislocalisation), could disrupt local
cilia phosphoinositide content and/or turnover and thereby the
localization and/or activity of phosphoinositide binding, cilia local-
ised proteins.
15. Conclusions
INPP5E and OCRL exhibit overlapping substrate speciﬁcity,
localisation to the primary cilia and regulate cilia function.
However, Lowe’s-affected individuals do not exhibit the classicalciliopathy phenotype. Therefore Lowe’s may represent a novel
class of ‘ciliopathy-associated’ syndromes. Future studies will be
required to determine the molecular processes by which INPP5E
and OCRL regulate cilia function and how mutations in these 5-
phosphtases lead to human diseases.
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